Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. - Wikidata - wikimedia - TriplyDB

Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.

Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.

http://www.wikidata.org/entity/Q33881052

about

A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine HSV-2: in pursuit of a vaccine The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine Varicella zoster vaccines and their implications for development of HSV vaccines T-helper cell-mediated proliferation and cytokine responses against recombinant Merkel cell polyomavirus-like particles.A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract.An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.Prospects and perspectives for development of a vaccine against herpes simplex virus infections.A mucosal vaccination approach for herpes simplex virus type 2.Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tract Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.Increased cell-mediated immune responses in patients with recurrent herpes simplex virus type 2 meningitis Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2 Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV.A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.The challenge of developing a herpes simplex virus 2 vaccine.An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells.CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization.Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.Novel rat models to study primary genital herpes simplex virus-2 infection.CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence.Preventing sexually transmitted infections: back to basics.

P2860

Q21089976-CE67FAA3-A033-4090-A101-197DE4B84512 Q22306291-3EB3F3EA-9EA4-4553-92C0-F4DA669F722C Q27021292-0E41CD3B-FD19-4EBD-8858-25E7F40146EB Q28280820-AC7E67F5-B008-4D66-9C1A-7970299209A2 Q31032531-8B2E68CD-1463-46CD-ADA0-0D26210E0ECE Q33825931-1F9BDC52-42EF-492F-BB20-34DBE33DD61B Q33870372-3937C752-9D4C-431F-9FC9-35CF600D49D2 Q33916162-2E86AE45-68B3-489E-A0F4-61B2F5C6058F Q34350019-72CEBCF6-33CA-4DD3-BC50-4F1B628C7A09 Q34431547-82BA593A-9FA5-404B-8882-13587C50A43E Q34558350-14028AAB-72F9-4E45-8953-73BED2FE6D92 Q34681733-F795DF8D-7AEC-4894-9CEE-B45B9E4CC38B Q35058245-670C4B6E-377F-4999-BDA1-0F1BC8A969C3 Q35066312-CB572259-CEB1-4C03-A4F1-2605E81D835E Q35076638-4685F75D-9B80-45C5-99A0-392F56055929 Q35133590-EABBA11F-F26A-4635-8CB8-C5BBF283955C Q35202180-1632D9D0-70E8-46C6-84BE-0A96C377B2AD Q35271194-02723842-E302-4BD7-BFC6-F6F5246FED18 Q35506920-52B3D52D-5A4F-40EA-B1BA-A0F2E980C512 Q35914367-CA5931D5-5BC2-404D-BFF8-DB8257DAF268 Q36601101-7E9F758F-9506-4351-B6BF-763B08911CD5 Q36671106-E16CA02B-4D6F-4457-A133-4AA7DED2A1D6 Q36759693-50CF1C89-BF07-4D3E-841B-DBD902172B76 Q36824210-8D60BA93-AB6B-4599-AD6A-2B6A23A19B87 Q37633921-FFC348A3-09A2-46A6-8F9B-00503FC0FF11 Q37679220-AAC1C1C2-80F8-461C-8B98-719CA620D456 Q37963480-D81889AC-15D2-4D7D-ADB1-AC8446B1644B Q38212516-BF007467-9E3D-4AF2-991C-924E13C24E0D Q38241377-890EF34F-70E6-4E2A-81F3-F2B28EDE33C0 Q41472497-F7F6F970-F871-4FF8-AA05-45B3CA194B4F Q42149041-6B6E3E46-8B5E-43D4-ACB9-4838C40A912B Q42590857-38AEA971-432A-4B6D-9901-14BE788E764C

P2860

Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.

http://www.wikidata.org/entity/Q33881052

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Detailed characterization of T ...... n immune seronegative persons.

@ast

Detailed characterization of T ...... n immune seronegative persons.

@en

type

label

Detailed characterization of T ...... n immune seronegative persons.

@ast

Detailed characterization of T ...... n immune seronegative persons.

@en

prefLabel

Detailed characterization of T ...... n immune seronegative persons.

@ast

Detailed characterization of T ...... n immune seronegative persons.

@en

P1433

Q33881052-A1033295-DAA7-43BB-8006-1202F5EE5AB9

P1476

Q33881052-2B3BDFEC-8A7F-4F45-8642-CC5E9DFD1D20

P2093

Q33881052-05EE3FAF-C3B5-4778-92D9-68DF0E18064F

Q33881052-40F61E35-2FC7-45E0-AEC0-FEF77DD59ACA

Q33881052-62487B15-A69A-4FEA-86C8-D1E5CA19BDFC

Q33881052-9F33B37B-9C51-40C0-A54B-E0618448B96F

Q33881052-D0AD8777-CC7B-4466-AA06-F16EF17DB4C5

P2860

Q33881052-00732DB2-328E-454F-8F63-FB7F230232CB

Q33881052-00F3102D-5F27-4945-AC91-F627C466E29D

Q33881052-094DF615-3A78-4267-B414-B6DB9583C097

Q33881052-0EACA867-DC8D-4373-B489-5289DAD5C342

Q33881052-12D42D22-7587-4AA9-AF47-CDE20E9C95B1

Q33881052-28675AC1-7185-4815-90F5-9FDA82F9267C

Q33881052-2E6522C1-5563-4C9C-8692-645928CA8100

Q33881052-38FF1980-A3A1-4B2F-9D2F-8344857C13EF

Q33881052-46E3E0EC-BD63-442D-A932-338DE929773F

Q33881052-53E52B41-ED3D-497F-8F4C-341C2D6C8636

P304

Q33881052-D49C48B9-294E-46C4-BCA7-5C04D25029E0

P31

Q33881052-EA6E1535-C3D6-449E-AF98-1A5AE36E5CBC

P356

Q33881052-5AC058FD-4E75-42E6-9729-3DA4A62325EE

P407

Q33881052-0A9E381D-8D1C-4F09-A436-8047C38A31C5

P433

Q33881052-ED3C0473-FBF1-4DE1-AB1C-8CDFACA1B20F

P478

Q33881052-AC1DF8B5-BB04-4A64-AF47-F50E75CFF199

P50

Q33881052-25C98AE0-1273-400E-97C3-E770D06EDADC

Q33881052-7811B253-0F58-4AD6-AF3C-6F8AF663832F

P577

Q33881052-8ACE229A-FF4A-45D1-8FEF-5577468F70AA

P5875

Q33881052-AB5100B4-9D1D-467D-B232-DF9D01268672

P698

Q33881052-5C7296FF-6249-4569-A073-1DF76790FDFB

P932

Q33881052-5964B4FF-B120-4104-8D2A-DB7795F326DF

P356

JIMMUNOL.0900722

P1433

Journal of Immunology

P1476

Detailed characterization of T ...... n immune seronegative persons.

@en

P2093

Amalia S Magaret

http://www.w3.org/2001/XMLSchema#string

Christine M Posavad

http://www.w3.org/2001/XMLSchema#string

Dawn E Mueller

http://www.w3.org/2001/XMLSchema#string

Lin Zhao

http://www.w3.org/2001/XMLSchema#string

Michael Remington

http://www.w3.org/2001/XMLSchema#string

P2860

Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA

Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes

Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users

Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes.

The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.

Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.

CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects.

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity.

P304

3250-3259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.0900722

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41465965

http://www.w3.org/2001/XMLSchema#string

P698

20164419

http://www.w3.org/2001/XMLSchema#string

P932

2877513

http://www.w3.org/2001/XMLSchema#string